Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 1, 2012, Pages 1-10

  Krishna, Gopal ^a   Ma, Lei ^a   Prasad, Pratapa ^a   Moton, Allen ^a   Martinho, Monika ^a   O'Mara, Edward ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antifungal; Drug interaction; Midazolam; Pharmacokinetics; Posaconazole; Simvastatin

Indexed keywords

CYTOCHROME P450 3A4; MIDAZOLAM; POSACONAZOLE; SIMVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDAZOLAM; MIDDLE AGED; SIMVASTATIN; TRIAZOLES; YOUNG ADULT;

EID: 84255182565     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.639360     Document Type: Article

References (41)

1. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59 (Pubitemid 46148777)
2. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47 (Pubitemid 46148776)
3. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12 (Pubitemid 44968977)
4. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42:1398-403
5. Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543-51 (Pubitemid 39129357)
6. Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004;21:645-53 (Pubitemid 38447146)
7. SP Europe. Noxafil 40 mg/ml oral suspension [Summary of Product Characteristics]. 2008
8. Merck & Co, Inc. ZOCOR- (simvastatin) tablets. 2008
9. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-41 (Pubitemid 28182231)
10. Schering Corp. NOXAFIL- (posaconazole) oral suspension. 2008
11. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-63 (Pubitemid 46167771)
12. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60 (Pubitemid 351265310)
13. Shen JX, Krishna G, Hayes RN. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J Pharm Biomed Anal 2007;43:228-36 (Pubitemid 44856187)
14. Krishna G, Moton A, Ma L, et al. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53:958-66
15. National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE). Natl Canc Inst Web Site 2006;1-72
16. Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro inhibition analysis of 8 cytochrome P450 (CYP) enzymes by voriconazole: major effect on CYPs 2B6, 2C9, 2C19 and 3A. Antimicrob Agents Chemother 2009;53:541-51
17. Pfizer, Inc. VFEND- I.V (voriconazole) for injection, VFEND- tablets (voriconazole), VFEND- (voriconazole) for oral suspension. 2007
18. Ishigam M, Uchiyama M, Kondo T, et al. Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions. Pharm Res 2001;18:622-31 (Pubitemid 32595790)
19. Isoherranen N, Kunze KL, Allen KE, et al. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004;32:1121-31 (Pubitemid 39287586)
20. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998;46:49-53 (Pubitemid 28308424)
21. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61 (Pubitemid 26279221)
22. Shaukat A, Benekli M, Vladutiu GD, et al. Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 2003;37:1032-5 (Pubitemid 36875235)
23. Kahri J, Valkonen M, Backlund T, et al. Rhabdomyolysis in a patient receiving atorvastatin and fluconazole. Eur J Clin Pharmacol 2005;60:905-7 (Pubitemid 40386163)
24. Hazin R, Abuzetun JY, Suker M, Porter J. Rhabdomyolysis induced by simvastatin-fluconazole combination. J Natl Med Assoc 2008;100:444-6 (Pubitemid 351556507)
25. Findling O, Meier N, Sellner J, et al. Clinical reasoning: rhabdomyolysis after combined treatment with simvastatin and fluconazole. Neurology 2008;71:e34-7
26. Rowan C, Brinker AD, Nourjah P, et al. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf 2009;18:301-9
27. Maxa JL, Melton LB, Ogu CC, et al. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. Ann Pharmacother 2002;36:820-3 (Pubitemid 34517411)
28. Krishna G, Moton A, Ma L, et al. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther 2009;31:286-98
29. Varhe A, Olkkola KT, Neuvonen PJ. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol 1996;42:465-70 (Pubitemid 26340147)
30. Olkkola KT, Ahonen J, Neuvonen PJ. The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anaesth Analg 1996;82:511-16 (Pubitemid 26072953)
31. Saari TI, Laine K, Leino K, et al. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 2006;79:362-70
32. Nivoix Y, Ubeaud-Sequier G, Engel P, et al. Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab 2009;10:395-409
33. Chen KY, Ko SC, Hsueh PR, et al. Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors. Chest 2001;120:177-84
34. Guengerich FP. Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 1997;43:7-35
35. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111-80 (Pubitemid 30122116)
36. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109:III50-7 (Pubitemid 38786444)
37. Hu M, To KK, Mak VW, Tomlinson B. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin Drug Metab Toxicol 2011;7:49-62
38. Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 2005;1:429-45
39. Templeton IE, Thummel KE, Kharasch ED, et al. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 2008;83:77-85
40. Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005;28:249-68 (Pubitemid 44698742)
41. Meyer Zu Schwabedissen HE, Bottcher K, Chaudhry A, et al. Liver X receptor alpha and farnesoid X receptor are major transcriptional regulators of OATP1B1. Hepatology 2010;52:1797-807